Phillips-Medisize announced today that it is collaborating with Subcuject to bring a wearable bolus injector to market.

Hudson, Wis.-based Phillips-Medisize, a Molex company, said in a news release that the on-body delivery system technology that is based on osmosis is now available for the next stage of drug-specific wearable injector solution after Subcuject filed for intellectual property of the concept.

The wearable osmotic bolus injector is designed as a low-cost, patient-friendly, pre-filled wearable injector for single use. It uses osmosis to generate the force to complete a full injection cycle and requires no additional electronics or batteries.

Phillips-Medisize and Subcuject said they are exploring the opportunity to meet the demand for larger-volume drug delivery, allowing patients to self-administer certain medications almost anywhere instead of relying upon healthcare professionals to do so in a clinical setting.

“We are very pleased to collaborate with Phillips-Medisize to complete the development and manufacturing needed to bring our product innovation to pharma customers successfully,” Subcuject CEO Jesper Roested said in the release. “Together, we can address the emerging need for inexpensive, prefilled, and single-use injectors that can deliver drugs at about 1mL per minute.”

“Teaming with Subcuject to develop an affordable, versatile wearable injector leverages our combined strengths and global expertise in proprietary device platforms,” added Phillips-Medisize president Paul Chaffin. “We’re excited to develop the technology and pave the way toward commercialization.”